Dominic Walsh, a business reporter who previously covered the leisure and drinks industry for The Times from 1997 to 2024, stated in post to X: ...

TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...

We recently compiled a list of the 10 Stocks Set to Explode in 2025. In this article, we are going to take a look at where TG ...

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

It's been a good week for TG Therapeutics, Inc. ( NASDAQ:TGTX ) shareholders, because the company has just released ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

TG Therapeutics Inc (TGTX) reports over 230% year-over-year revenue growth, raises full-year guidance, and outlines future ...

NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: TGTX), today announced that a conference call will be held, Monday November 4, 2024, at 8:30 AM ET ...